Clinical Trials List
2023-09-15 - 2025-10-22
Phase III
Not yet recruiting2
Terminated3
Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight and obesity (STEP 12)
-
Sponsor
台灣諾和諾德藥品故份有限公司
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/10/31
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Completed
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Semaglutide
Semaglutide
Semaglutide
Semaglutide
Dosage Form
Dosage
1.34 mg/mL
1.34 mg/mL
2.27 mg/mL
3.2 mg/mL
Endpoints
Inclution Criteria
• Body mass index (BMI) of ≥ 24 and < 28 kg/m2 with the presence of at least one
weight-related complication (treated or untreated): T2D, hypertension, dyslipidaemia,
obstructive sleep apnoea or cardiovascular disease or BMI ≥ 28 and < 30 kg/m2, with or
without weight-related complications at screening.
• History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion Criteria
medical records.
• Treatment with any medication for the indication of obesity within the past 90 days before
screening.
• Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary
thyroid carcinoma.
The Estimated Number of Participants
-
Taiwan
80 participants
-
Global
242 participants
